Skip to main content
2024 DC-CSEM Conference Main banner
On-Demand

Accredited Symposium

AS2404 - Clinical Strategies: Advancements in Basal Insulin for T2D

Friday, November 22, 2024
13:00 - 14:00 AT Time
Location: Ballroom B3

    Presenter(s)

  • AA

    Alex Abitbol, MD

    Disclosure information not submitted.

  • KL

    KIRSTIE LITHGOW, MD FRCPC (she/her/hers)

    Assistant Clinical Professor
    University of Calgary
    Cumming School of Medicine
    Calgary, Alberta, Canada

    Disclosure(s): AAA/Novartis: Consultant (Terminated); Pfizer: Grant/Research Support (Ongoing)

  • Stacey Smith, BSc Pharmacy, CDE, CBE

    Pharmacist
    Nova Scotia Health Authority
    Fall River, Nova Scotia, Canada

    Disclosure(s): Abbott Diabetes: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Dexcom Canada: Speaker/Honoraria (Ongoing); Novo Nordisk Canada: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing)

  • GIHANE ZARIFA, MD, MS, FCFP

    Staff MD and Diabetes chronic disease management lead MD,
    Trillium Health Partners (THP) - The Credit Valley Hospital (Family Health Team)
    University of Toronto
    Georgetown, Ontario, Canada

    Disclosure(s): Bayer Canada: Speaker/Honoraria (Terminated); CCRN: Committee/Planning Member (Ongoing); Diabetes Simplified: Committee/Planning Member (Ongoing), Speaker/Honoraria (Ongoing); Eisai Pharmaceuticals: Speaker/Honoraria (Terminated); Eli Lilly: Committee/Planning Member (Terminated); Novonordisk: Advisory Board (Ongoing), Committee/Planning Member (Ongoing), Speaker/Honoraria (Ongoing)

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada and approved by the Canadian Society of Endocrinology and Metabolism.
This accredited symposium was co-developed with the Canadian Society of Endocrinology and Metabolism and Novo Nordisk and was planned to achieve scientific integrity, objectivity and balance.

Learning Objectives:

  • Recognize the evolution of basal insulin therapy and evaluate the role of once-weekly basal insulin in the management of T2D.
  • Compare the clinical considerations for initiating once-weekly basal insulin in insulin-naïve patients versus switching from other basal insulins in patients with T2D.
  • Apply evidence-based strategies for initiating, titrating, and managing patients on once-weekly basal insulin therapy, including proper usage, dosing, administration safety, monitoring, and patient counselling.